efenamic Acid as Steroid-sparing Antiinflammatory Drug During Viral Phase of COVID-19: 5 Case Reports
Keywords:
Mefenamic acid,, steroid-sparing anti-inflammatory drugs, COVID-19, fenamates, NLRP3 inflammasomeAbstract
The diverse disease manifestations in coronavirus disease 2019 (COVID-19) patients are an enigma since some cases display
little to no symptoms, whereas others develop severe fever and pneumonia, leading to acute respiratory distress syndrome
and eventually death. Given the excessive inflammatory activity, there is a need to target a regulator of cellular inflammation
while leaving the antiviral pathways intact. Corticosteroids are used as potent anti-inflammatory agents; however, it may
also be linked with attenuation of viral clearance leading to nonuniform benefits across the disease spectrum. Mefenamic acid
can be used as a steroid-sparing, long-term drug in the management of COVID-19 and post-COVID inflammation. In this
article, the management of 5 mild-to-moderate COVID-19 cases using steroid-sparing anti-inflammatory agents is described.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
